Biocon informs about company statement

08 Sep 2021 Evaluate

Biocon has informed that the company and its subsidiaries Biocon Pharma \ and Biocon Pharma Inc. (‘Biocon’) has entered into a confidential settlement agreement with Celgene Corporation (Celgene), a wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY), relating to patents for REVLIMID® (lenalidomide).” The above information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.

Biocon Share Price

316.15 -4.65 (-1.45%)
31-Oct-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1849.05
Dr. Reddys Lab 1274.25
Cipla 1553.20
Lupin 2184.00
Zydus Lifesciences 1001.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.